The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Silo enters into commercial evaluation license agreement for next generation liposomes
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Bayer now present in four of the largest biotechnology hubs in the United States
Subscribe To Our Newsletter & Stay Updated
